alpha-lactalbumin vaccine / Anixa Biosci, Cleveland Clinic 
Welcome,         Profile    Billing    Logout  
  Diseases    Trials    Trials    News 
  • ||||||||||  alpha-lactalbumin vaccine / Anixa Biosci, Cleveland Clinic
    Trial completion date, Trial primary completion date, Metastases:  CASE6119: Adjuvant Therapy With an Alpha-lactalbumin Vaccine in Triple-Negative Breast Cancer (clinicaltrials.gov) -  May 15, 2024   
    P1,  N=45, Recruiting, 
    Data from this trial will be insufficient to assess clinical efficacy and will be explored in Phase II.View this table:View inline View popup Download powerpoint Abstract 631 Table 1 CTCAE injection site reactions by dose level and grade Trial completion date: Sep 2024 --> Mar 2025 | Trial primary completion date: May 2024 --> Nov 2024
  • ||||||||||  alpha-lactalbumin vaccine / Anixa Biosci, Cleveland Clinic
    Enrollment change, Trial completion date, Trial primary completion date, Metastases:  CASE6119: Adjuvant Therapy With an Alpha-lactalbumin Vaccine in Triple-Negative Breast Cancer (clinicaltrials.gov) -  Dec 28, 2023   
    P1,  N=45, Recruiting, 
    Trial completion date: Sep 2024 --> Mar 2025 | Trial primary completion date: May 2024 --> Nov 2024 N=30 --> 45 | Trial completion date: Sep 2023 --> Sep 2024 | Trial primary completion date: Jun 2023 --> May 2024
  • ||||||||||  alpha-lactalbumin vaccine / Anixa Biosci, Cleveland Clinic
    Phase I trial of alpha-lactalbumin vaccine in high-risk operable triple-negative breast cancer (Section 28; Poster Board #7) -  Mar 14, 2023 - Abstract #AACR2023AACR_5289;    
    Accrual to dose levels 1 and 2 will be expanded to further define toxicity and immunologic effects. Accrual of patients with BRCA1 or PALB2 mutations planning to undergo prophylactic mastectomy is beginning in order to define the toxicity and immunologic effects in this group and to determine whether inflammatory changes from occult lactational foci will be produced.
  • ||||||||||  alpha-lactalbumin vaccine / Anixa Biosci, Cleveland Clinic
    Trial primary completion date, Metastases:  CASE6119: Adjuvant Therapy With an Alpha-lactalbumin Vaccine in Triple-Negative Breast Cancer (clinicaltrials.gov) -  Feb 6, 2023   
    P1,  N=30, Recruiting, 
    Accrual of patients with BRCA1 or PALB2 mutations planning to undergo prophylactic mastectomy is beginning in order to define the toxicity and immunologic effects in this group and to determine whether inflammatory changes from occult lactational foci will be produced. Trial primary completion date: Dec 2022 --> Jun 2023
  • ||||||||||  alpha-lactalbumin vaccine / Anixa Biosci, Cleveland Clinic
    Trial completion date, Trial primary completion date, Metastases:  CASE6119: Adjuvant Therapy With an Alpha-lactalbumin Vaccine in Triple-Negative Breast Cancer (clinicaltrials.gov) -  Jul 5, 2022   
    P1,  N=30, Recruiting, 
    Trial primary completion date: Dec 2022 --> Jun 2023 Trial completion date: Sep 2022 --> Sep 2023 | Trial primary completion date: May 2022 --> Dec 2022
  • ||||||||||  alpha-lactalbumin vaccine / Anixa Biosci, Cleveland Clinic
    Trial completion date, Trial initiation date, Trial primary completion date, Metastases:  CASE6119: Adjuvant Therapy With an Alpha-lactalbumin Vaccine in Triple-Negative Breast Cancer (clinicaltrials.gov) -  Jun 1, 2021   
    P1,  N=30, Not yet recruiting, 
    Not yet recruiting --> Recruiting Trial completion date: Dec 2021 --> Sep 2022 | Initiation date: Mar 2021 --> Jul 2021 | Trial primary completion date: Oct 2021 --> Jul 2022